Prevention and treatment – Media Watch
By JournAIDS According to newspaper reports, the jury is out over the potential benefits and losses of a home-grown, state-owned pharmaceutical company.
Continue reading | 21 July 2011 | 0 Comments | Tags: anc lekgotla, art, arvs, aspen, cost of art, gilead, gwede mantashe, healthcare, medicines patent pool, pharmaceutical, piasa, sowetan, state drug company, the citizen
By Kim Johnson HIV coverage continues to be dominated by the latest, and possibly one of the greatest, breakthroughs in HIV prevention. The potential two pronged approach to HIV prevention would see ARVs administered to HIV-negative
and HIV-positive people.
Continue reading | 19 July 2011 | 0 Comments | Tags: aids denialism, art, arvs, hiv prevention, hiv-positive teens, ias conference, news24, plusnews, politics, the times, treatment as prevention
By Kim Johnson An error ridden article by the South African Press Association (SAPA) has been used by various newspapers to report on a particular HIV-related landmark development.
Continue reading | 14 July 2011 | 0 Comments | Tags: accuracy, art, arvs, hiv prevention, journalism, news media, prep, research, sapa, terminology, the star
By JournAIDS An article in today's edition of
The New Age (TNA) which reports on multiple concurrent partnerships (MCP) presents a somewhat one sided view of the different perspectives on the role of MCP in the HIV epidemic.
Continue reading | 13 July 2011 | 0 Comments | Tags: balance, discrete multiple partnerships, journalism, mcp, multiple partnerships, the new age
By JournAIDS An agreement between Gilead Sciences and the Medicines Patent Pool will allow developing countries to curb HIV through cheap ARVs; the effect might however be limited by a lack of provision of ARVs used in second line therapy.
Continue reading | 13 July 2011 | 0 Comments | Tags: art, arvs, cheap arvs, first line therapy, gilead, medicines patent pool, quad, second line therapy
Dr Gita Ramjee, University of Kwa-Zulu Natal (UKZN) alumnus and head… Read more
